Clinical Research in Cardiology

, Volume 102, Issue 1, pp 1–10 | Cite as

Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review

  • Paulino A. Alvarez
  • Ernst R. Schwarz
  • Rajesh Ramineni
  • Phil Myatt
  • Clay Barbin
  • Carlos Boissonnet
  • Anita Phan
  • Aldo Maggioni
  • Alejandro BarbagelataEmail author



Cell therapy (CTh) is a promising novel therapy for myocardial infarction (MI) and ischemic cardiomyopathy (iCMP). Recognizing adverse events (AE) is important for safety evaluation, harm prevention and may aid in the design of future trials.


To define the prevalence of periprocedural AE in CTh trials in MI and iCMP.


A literature search was conducted using the MEDLINE database from January 1990 to October 2010. Controlled clinical trials that compared CTh with standard treatment in the setting of MI and/or iCMP were selected. AE related to CTh were analyzed.


A total of 2,472 patients from 35 trials were included. There were 26 trials including 1,796 patients that used CTh in MI and 9 trials including 676 patients that used CTh in iCMP. Periprocedural arrhythmia monitoring protocols were heterogeneous and follow-up was short in most of the trials. In MI trials, the incidence of periprocedural adverse events (AE) related to intracoronary cell transplantation was 7.5 % (95 % CI 6.04–8.96 %). AE related to granulocyte colony-stimulating factor (GCS-F) used for cell mobilization for peripheral apheresis was 16 % (95 % CI 9.44–22.56 %). During intracoronary transplantation in iCMP, the incidence of periprocedural AE incidence was 2.6 % (95 % CI 0.53–4.67 %). There were no AE reported during transepicardial transplantation and AE were rare during transendocardial transplantation.


The majority of periprocedural AE in CTh trials in MI occurred during intracoronary transplantation and GCS-F administration. In iCMP, periprocedural AE were uncommon. Avoiding intracoronary route for CTh implantation may decrease the burden of periprocedural AE. Standardization of AE definition in CTh trials is needed.


Myocardial infarction Cell therapy Adverse events Cardiomyopathy 


Conflict of interest

The authors have no potential conflict of interest to declare.


  1. 1.
    Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D (2002) Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106(24):3068–3072PubMedCrossRefGoogle Scholar
  2. 2.
    Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347(18):1397–1402. doi: 10.1056/NEJMoa020265347/18/1397 PubMedCrossRefGoogle Scholar
  3. 3.
    Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 292(3):344–350. doi: 10.1001/jama.292.3.344292/3/344 PubMedCrossRefGoogle Scholar
  4. 4.
    Briffa T, Hickling S, Knuiman M, Hobbs M, Hung J, Sanfilippo FM, Jamrozik K, Thompson PL (2009) Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984–2005. BMJ 338:b36PubMedCrossRefGoogle Scholar
  5. 5.
    Loffredo FS, Steinhauser ML, Gannon J, Lee RT (2011) Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 8(4):389–398. doi: 10.1016/j.stem.2011.02.002 PubMedCrossRefGoogle Scholar
  6. 6.
    Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J, Vanderheyden M, Kim HS, Kang HJ, Strauer BE, Vetrovec GW (2007) Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 50(18):1761–1767. doi: 10.1016/j.jacc.2007.07.041 PubMedCrossRefGoogle Scholar
  7. 7.
    Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM (2008) Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 29(15):1807–1818. doi: 10.1093/eurheartj/ehn220 PubMedCrossRefGoogle Scholar
  8. 8.
    Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B (2007) Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167(10):989–997. doi: 10.1001/archinte.167.10.989 PubMedCrossRefGoogle Scholar
  9. 9.
    Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 117(2):296–329. doi: 10.1161/CIRCULATIONAHA.107.188209 PubMedCrossRefGoogle Scholar
  10. 10.
    Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14):1977–2016. doi: 10.1161/CIRCULATIONAHA.109.192064 PubMedCrossRefGoogle Scholar
  11. 11.
    Macia E, Boyden PA (2009) Stem cell therapy is proarrhythmic. Circulation 119(13):1814–1823. doi: 10.1161/CIRCULATIONAHA.108.779900 PubMedCrossRefGoogle Scholar
  12. 12.
    Ly HQ, Nattel S (2009) Stem cells are not proarrhythmic: letting the genie out of the bottle. Circulation 119(13):1824–1831. doi: 10.1161/CIRCULATIONAHA.108.812701 PubMedCrossRefGoogle Scholar
  13. 13.
    Menasche P (2010) Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol 50(2):258–265. doi: 10.1016/j.yjmcc.2010.06.010 PubMedCrossRefGoogle Scholar
  14. 14.
    Chien KR (2004) Stem cells: lost in translation. Nature 428(6983):607–608. doi: 10.1038/nature02500nature02500 PubMedCrossRefGoogle Scholar
  15. 15.
    Boyle AJ, Schulman SP, Hare JM, Oettgen P (2006) Is stem cell therapy ready for patients? Stem cell therapy for cardiac repair: ready for the next step. Circulation 114(4):339–352. doi: 10.1161/CIRCULATIONAHA.105.590653 PubMedCrossRefGoogle Scholar
  16. 16.
    Atkinson AJAD, Daniels CE, Dedrick RL, Markey SP (2007) Principles of clinical pharmacology, 2nd edn. Academic Press, San DiegoGoogle Scholar
  17. 17.
    Ince H, Petzsch M, Rehders TC, Chatterjee T, Nienaber CA (2004) Transcatheter transplantation of autologous skeletal myoblasts in postinfarction patients with severe left ventricular dysfunction. J Endovasc Ther 11(6):695–704. doi: 10.1583/04-1386R.1 PubMedCrossRefGoogle Scholar
  18. 18.
    Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H (2004) Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364(9429):141–148. doi: 10.1016/S0140-6736(04)16626-9 PubMedCrossRefGoogle Scholar
  19. 19.
    Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B, De Bondt P, Van Haute I, Lootens N, Heyndrickx G, Wijns W (2005) Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 112(9 Suppl):I178–I183. doi: 10.1161/CIRCULATIONAHA.104.522292 PubMedGoogle Scholar
  20. 20.
    Karpov RS, Popov SV, Markov VA, Suslova TE, Ryabov VV, Poponina YS, Krylov AL, Sazonova SV (2005) Autologous mononuclear bone marrow cells during reparative regeneration after acute myocardial infarction. Bull Exp Biol Med 140(5):640–643PubMedCrossRefGoogle Scholar
  21. 21.
    Katritsis DG, Sotiropoulou PA, Karvouni E, Karabinos I, Korovesis S, Perez SA, Voridis EM, Papamichail M (2005) Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 65(3):321–329. doi: 10.1002/ccd.20406 PubMedCrossRefGoogle Scholar
  22. 22.
    Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM (2006) Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355(12):1222–1232. doi: 10.1056/NEJMoa051779 PubMedCrossRefGoogle Scholar
  23. 23.
    Hendrikx M, Hensen K, Clijsters C, Jongen H, Koninckx R, Bijnens E, Ingels M, Jacobs A, Geukens R, Dendale P, Vijgen J, Dilling D, Steels P, Mees U, Rummens JL (2006) Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation 114(1 Suppl):I101–I107. doi: 10.1161/CIRCULATIONAHA.105.000505 PubMedGoogle Scholar
  24. 24.
    Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F (2006) Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367(9505):113–121. doi: 10.1016/S0140-6736(05)67861-0 PubMedCrossRefGoogle Scholar
  25. 25.
    Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K (2006) Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 355(12):1199–1209. doi: 10.1056/NEJMoa055706 PubMedCrossRefGoogle Scholar
  26. 26.
    Meluzin J, Janousek S, Mayer J, Groch L, Hornacek I, Hlinomaz O, Kala P, Panovsky R, Prasek J, Kaminek M, Stanicek J, Klabusay M, Koristek Z, Navratil M, Dusek L, Vinklarkova J (2008) Three-, 6-, and 12-month results of autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction. Int J Cardiol 128(2):185–192. doi: 10.1016/j.ijcard.2007.04.098 PubMedCrossRefGoogle Scholar
  27. 27.
    Meluzin J, Mayer J, Groch L, Janousek S, Hornacek I, Hlinomaz O, Kala P, Panovsky R, Prasek J, Kaminek M, Stanicek J, Klabusay M, Koristek Z, Navratil M, Dusek L, Vinklarkova J (2006) Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function. Am Heart J 152(5):975.e9-15. doi: 10.1016/j.ahj.2006.08.004 PubMedCrossRefGoogle Scholar
  28. 28.
    Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355(12):1210–1221. doi: 10.1056/NEJMoa060186 PubMedCrossRefGoogle Scholar
  29. 29.
    Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM (2006) Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 27(23):2775–2783. doi: 10.1093/eurheartj/ehl388 PubMedCrossRefGoogle Scholar
  30. 30.
    Penicka M, Horak J, Kobylka P, Pytlik R, Kozak T, Belohlavek O, Lang O, Skalicka H, Simek S, Palecek T, Linhart A, Aschermann M, Widimsky P (2007) Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction: a prematurely terminated randomized study. J Am Coll Cardiol 49(24):2373–2374. doi: 10.1016/j.jacc.2007.04.009 PubMedCrossRefGoogle Scholar
  31. 31.
    de Lezo JS, Herrera C, Pan M, Romero M, Pavlovic D, Segura J, Sanchez J, Ojeda S, Torres A (2007) Regenerative therapy in patients with a revascularized acute anterior myocardial infarction and depressed ventricular function. Rev Esp Cardiol 60(4):357–365 pii: 13101639CrossRefGoogle Scholar
  32. 32.
    Huikuri HV, Kervinen K, Niemela M, Ylitalo K, Saily M, Koistinen P, Savolainen ER, Ukkonen H, Pietila M, Airaksinen JK, Knuuti J, Makikallio TH (2008) Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 29(22):2723–2732. doi: 10.1093/eurheartj/ehn436 PubMedCrossRefGoogle Scholar
  33. 33.
    Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagege AA (2008) The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117(9):1189–1200. doi: 10.1161/CIRCULATIONAHA.107.734103 PubMedCrossRefGoogle Scholar
  34. 34.
    Veltman CE, Soliman OI, Geleijnse ML, Vletter WB, Smits PC, ten Cate FJ, Jordaens LJ, Balk AH, Serruys PW, Boersma E, van Domburg RT, van der Giessen WJ (2008) Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy. Eur Heart J 29(11):1386–1396. doi: 10.1093/eurheartj/ehn171 PubMedCrossRefGoogle Scholar
  35. 35.
    Peruga J, Plewka M, Kasprzak J, Jezewski T, Wierzbicka A, Robak T, Krzeminska-Pakula M (2009) Intracoronary administration of stem cells in patients with acute myocardial infarction: angiographic follow-up. Kardiol Pol 67(5):477–484 pii: 12451PubMedGoogle Scholar
  36. 36.
    Plewka M, Krzeminska-Pakula M, Lipiec P, Peruga JZ, Jezewski T, Kidawa M, Wierzbowska-Drabik K, Korycka A, Robak T, Kasprzak JD (2009) Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction. Am J Cardiol 104(10):1336–1342. doi: 10.1016/j.amjcard.2009.06.057 PubMedCrossRefGoogle Scholar
  37. 37.
    Tendera M, Wojakowski W, Ruzyllo W, Chojnowska L, Kepka C, Tracz W, Musialek P, Piwowarska W, Nessler J, Buszman P, Grajek S, Breborowicz P, Majka M, Ratajczak MZ (2009) Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 30(11):1313–1321. doi: 10.1093/eurheartj/ehp073 PubMedCrossRefGoogle Scholar
  38. 38.
    Yousef M, Schannwell CM, Kostering M, Zeus T, Brehm M, Strauer BE (2009) The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 53(24):2262–2269. doi: 10.1016/j.jacc.2009.02.051 PubMedCrossRefGoogle Scholar
  39. 39.
    Strauer BE, Yousef M, Schannwell CM (2010) The acute and long-term effects of intracoronary stem cell transplantation in 191 patients with chronic heart failure: the STAR-heart study. Eur J Heart Fail 12(7):721–729. doi: 10.1093/eurjhf/hfq095 PubMedCrossRefGoogle Scholar
  40. 40.
    Wohrle J, Merkle N, Mailander V, Nusser T, Schauwecker P, von Scheidt F, Schwarz K, Bommer M, Wiesneth M, Schrezenmeier H, Hombach V (2009) Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol 105(6):804–812. doi: 10.1016/j.amjcard.2009.10.060 CrossRefGoogle Scholar
  41. 41.
    Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP (2004) Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 94(1):92–95. doi: 10.1016/j.amjcard.2004.03.034 PubMedCrossRefGoogle Scholar
  42. 42.
    Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Lee DS, Sohn DW, Han KS, Oh BH, Lee MM, Park YB (2004) Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363(9411):751–756. doi: 10.1016/S0140-6736(04)15689-4 PubMedCrossRefGoogle Scholar
  43. 43.
    Ruan W, Pan CZ, Huang GQ, Li YL, Ge JB, Shu XH (2005) Assessment of left ventricular segmental function after autologous bone marrow stem cells transplantation in patients with acute myocardial infarction by tissue tracking and strain imaging. Chin Med J 118(14):1175–1181 (Engl)PubMedGoogle Scholar
  44. 44.
    Chen S, Liu Z, Tian N, Zhang J, Yei F, Duan B, Zhu Z, Lin S, Kwan TW (2006) Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 18(11):552–556PubMedGoogle Scholar
  45. 45.
    Gao LR, Wang ZG, Zhu ZM, Fei YX, He S, Tian HT, Zhang NK, Chen Y, Xu HT, Yang Y (2006) Effect of intracoronary transplantation of autologous bone marrow-derived mononuclear cells on outcomes of patients with refractory chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol 98(5):597–602. doi: 10.1016/j.amjcard.2006.03.034 PubMedCrossRefGoogle Scholar
  46. 46.
    Ge J, Li Y, Qian J, Shi J, Wang Q, Niu Y, Fan B, Liu X, Zhang S, Sun A, Zou Y (2006) Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction (TCT-STAMI). Heart 92(12):1764–1767. doi: 10.1136/hrt.2005.085431 PubMedCrossRefGoogle Scholar
  47. 47.
    Kang HJ, Lee HY, Na SH, Chang SA, Park KW, Kim HK, Kim SY, Chang HJ, Lee W, Kang WJ, Koo BK, Kim YJ, Lee DS, Sohn DW, Han KS, Oh BH, Park YB, Kim HS (2006) Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation 114(1 Suppl):I145–I151. doi: 10.1161/CIRCULATIONAHA.105.001107 PubMedGoogle Scholar
  48. 48.
    Li ZQ, Zhang M, Jing YZ, Zhang WW, Liu Y, Cui LJ, Yuan L, Liu XZ, Yu X, Hu TS (2007) The clinical study of autologous peripheral blood stem cell transplantation by intracoronary infusion in patients with acute myocardial infarction (AMI). Int J Cardiol 115(1):52–56. doi: 10.1016/j.ijcard.2006.04.005 PubMedCrossRefGoogle Scholar
  49. 49.
    Choi JH, Choi J, Lee WS, Rhee I, Lee SC, Gwon HC, Lee SH, Choe YH, Kim DW, Suh W, Kim DK, Jeon ES (2007) Lack of additional benefit of intracoronary transplantation of autologous peripheral blood stem cell in patients with acute myocardial infarction. Circ J 71(4):486–494. doi: JST.JSTAGE/circj/71.486 PubMedCrossRefGoogle Scholar
  50. 50.
    Tatsumi T, Ashihara E, Yasui T, Matsunaga S, Kido A, Sasada Y, Nishikawa S, Hadase M, Koide M, Nakamura R, Irie H, Ito K, Matsui A, Matsui H, Katamura M, Kusuoka S, Matoba S, Okayama S, Horii M, Uemura S, Shimazaki C, Tsuji H, Saito Y, Matsubara H (2007) Intracoronary transplantation of non-expanded peripheral blood-derived mononuclear cells promotes improvement of cardiac function in patients with acute myocardial infarction. Circ J 71(8):1199–1207. doi: JST.JSTAGE/circj/71.1199 PubMedCrossRefGoogle Scholar
  51. 51.
    Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, Rossi MI, Carvalho AC, Dutra HS, Dohmann HJ, Silva GV, Belem L, Vivacqua R, Rangel FO, Esporcatte R, Geng YJ, Vaughn WK, Assad JA, Mesquita ET, Willerson JT (2003) Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107(18):2294–2302. doi: 10.1161/01.CIR.0000070596.30552.8B PubMedCrossRefGoogle Scholar
  52. 52.
    Patel AN, Geffner L, Vina RF, Saslavsky J, Urschel HC Jr, Kormos R, Benetti F (2005) Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J Thorac Cardiovasc Surg 130(6):1631–1638. doi: 10.1016/j.jtcvs.2005.07.056 PubMedCrossRefGoogle Scholar
  53. 53.
    Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54(24):2277–2286. doi: 10.1016/j.jacc.2009.06.055 PubMedCrossRefGoogle Scholar
  54. 54.
    Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A, Drexler H (2006) Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (Bone marrow transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113(10):1287–1294. doi: 10.1161/CIRCULATIONAHA.105.575118 PubMedCrossRefGoogle Scholar
  55. 55.
    Wohrle J, Merkle N, Mailander V, Nusser T, Schauwecker P, von Scheidt F, Schwarz K, Bommer M, Wiesneth M, Schrezenmeier H, Hombach V (2010) Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol 105(6):804–812. doi: 10.1016/j.amjcard.2009.10.060 PubMedCrossRefGoogle Scholar
  56. 56.
    Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Forfang K (2005) Autologous stem cell transplantation in acute myocardial infarction: the ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J 39(3):150–158PubMedCrossRefGoogle Scholar
  57. 57.
    Meyer GP, Wollert KC, Lotz J, Pirr J, Rager U, Lippolt P, Hahn A, Fichtner S, Schaefer A, Arseniev L, Ganser A, Drexler H (2009) Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 30(24):2978–2984. doi: 10.1093/eurheartj/ehp374 PubMedCrossRefGoogle Scholar
  58. 58.
    Kang HJ, Kim HS, Koo BK, Kim YJ, Lee D, Sohn DW, Oh BH, Park YB (2007) Intracoronary infusion of the mobilized peripheral blood stem cell by G-CSF is better than mobilization alone by G-CSF for improvement of cardiac function and remodeling: 2-year follow-up results of the myocardial regeneration and angiogenesis in myocardial infarction with G-CSF and intra-coronary stem cell infusion (MAGIC Cell) 1 trial. Am Heart J 153(2):237e231–237e238. doi: 10.1016/j.ahj.2006.11.004 CrossRefGoogle Scholar
  59. 59.
    Engel D, Peshock R, Armstong RC, Sivasubramanian N, Mann DL (2004) Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. Am J Physiol Heart Circ Physiol 287(3):H1303–H1311. doi: 10.1152/ajpheart.00053.2004 PubMedCrossRefGoogle Scholar
  60. 60.
    Grady KL, Dracup K, Kennedy G, Moser DK, Piano M, Stevenson LW, Young JB (2000) Team management of patients with heart failure: a statement for healthcare professionals from The Cardiovascular Nursing Council of the American Heart Association. Circulation 102(19):2443–2456PubMedCrossRefGoogle Scholar
  61. 61.
    McDermott MM (2007) The international pandemic of chronic cardiovascular disease. JAMA 297(11):1253–1255. doi: 10.1001/jama.297.11.1253 PubMedCrossRefGoogle Scholar
  62. 62.
    Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107(25):3133–3140. doi: 10.1161/01.CIR.0000077913.60364.D2 PubMedCrossRefGoogle Scholar
  63. 63.
    Beohar N, Rapp J, Pandya S, Losordo DW (2010) Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am Coll Cardiol 56(16):1287–1297. doi: 10.1016/j.jacc.2010.05.039 PubMedCrossRefGoogle Scholar
  64. 64.
    Guyatt GH, Sackett DL, Cook DJ (1994) Users’ guides to the medical literature. II: how to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 271(1):59–63PubMedCrossRefGoogle Scholar
  65. 65.
    Singh JA, Wells GA, Christensen R, Ghogomu ET, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 16(2):CD008794. doi: 10.1002/14651858.CD008794.pub2 Google Scholar
  66. 66.
    Ioannidis JP, Lau J (2001) Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 285(4):437–443. doi: joc00579 PubMedCrossRefGoogle Scholar
  67. 67.
    Ioannidis JP, Contopoulos-Ioannidis DG (1998) Reporting of safety data from randomised trials. Lancet 352(9142):1752–1753. doi: 10.1016/S0140-6736(05)79825-1 PubMedCrossRefGoogle Scholar
  68. 68.
    Vulliet PR, Greeley M, Halloran SM, MacDonald KA, Kittleson MD (2004) Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet 363(9411):783–784. doi: 10.1016/S0140-6736(04)15695-X PubMedCrossRefGoogle Scholar
  69. 69.
    Kamota T, Li TS, Morikage N, Murakami M, Ohshima M, Kubo M, Kobayashi T, Mikamo A, Ikeda Y, Matsuzaki M, Hamano K (2009) Ischemic pre-conditioning enhances the mobilization and recruitment of bone marrow stem cells to protect against ischemia/reperfusion injury in the late phase. J Am Coll Cardiol 53(19):1814–1822. doi: 10.1016/j.jacc.2009.02.015 PubMedCrossRefGoogle Scholar
  70. 70.
    Ince H, Valgimigli M, Petzsch M, de Lezo JS, Kuethe F, Dunkelmann S, Biondi-Zoccai G, Nienaber CA (2008) Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis. Heart 94(5):610–616. doi: 10.1136/hrt.2006.111385 PubMedCrossRefGoogle Scholar
  71. 71.
    Makkar RR, Lill M, Chen PS (2003) Stem cell therapy for myocardial repair: is it arrhythmogenic? J Am Coll Cardiol 42(12):2070–2072 pii: S0735109703012774PubMedCrossRefGoogle Scholar
  72. 72.
    Menasche P (2009) Stem cell therapy for heart failure: are arrhythmias a real safety concern? Circulation 119(20):2735–2740. doi: 10.1161/CIRCULATIONAHA.108.812693 PubMedCrossRefGoogle Scholar
  73. 73.
    Menasche P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, Bel A, Sarateanu S, Scorsin M, Schwartz K, Bruneval P, Benbunan M, Marolleau JP, Duboc D (2003) Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 41(7):1078–1083 pii: S0735109703000925PubMedCrossRefGoogle Scholar
  74. 74.
    Bousquet C, Lagier G, Louet AL-L, Le Beller C, Venot A, Jaulent MC (2005) Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf 28(1):19–34PubMedCrossRefGoogle Scholar
  75. 75.
    Qaseem A, Alguire P, Dallas P, Feinberg LE, Fitzgerald FT, Horwitch C, Humphrey L, Leblond R, Moyer D, Wiese JG, Weinberger S (2012) Appropriate use of screening and diagnostic tests to foster high-value, cost-conscious care. Ann Intern Med 156(2):147–149. doi: 10.1059/0003-4819-156-2-201201170-00011 PubMedGoogle Scholar
  76. 76.
    Wollert KC, Drexler H (2010) Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol 7(4):204–215. doi: 10.1038/nrcardio.2010.1 PubMedCrossRefGoogle Scholar
  77. 77.
    Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365(18):1673–1683. doi: 10.1056/NEJMoa1106152 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Paulino A. Alvarez
    • 1
  • Ernst R. Schwarz
    • 2
  • Rajesh Ramineni
    • 3
  • Phil Myatt
    • 3
  • Clay Barbin
    • 3
  • Carlos Boissonnet
    • 4
  • Anita Phan
    • 2
  • Aldo Maggioni
    • 5
  • Alejandro Barbagelata
    • 3
    • 6
    Email author
  1. 1.Hospital de Clínicas José de San MartinUniversidad de Buenos AiresBuenos AiresArgentina
  2. 2.Cedars Sinai Heart InstituteLos AngelesUSA
  3. 3.University of Texas Medical BranchGalvestonUSA
  4. 4.Centro de Educación Médica e Investigaciones ClínicasBuenos AiresArgentina
  5. 5.FlorenceItaly
  6. 6.GalvestonUSA

Personalised recommendations